Location of Repository

Reactivation of Hepatitis B in a Patient with Breast Cancer Treated Using Capecitabine

By Marco Fiore, Ivo Maria Crosato, Rossana Bussani, Romina Valentinotti, Marta Mascarello and Roberto Luzzati


Reactivation of hepatitis B virus (HBV) is a well-recognized complication following immunosuppressive drug therapy in patients with past infection. The International Guidelines for HBV screening before cytotoxic or immunosuppressive therapy are controversial, there is only agreement on the use of biological agent such as anti-CD 20. The literature data do not report HBV reactivation due to capecitabine and therefore the international guidelines do not recommend prophylaxis in that condition. In this paper, we describe the history of HBV reactivation of hepatitis B in a female patient with breast cancer treated using capecitabine observed in a Unit of Infectious Diseases of north-est of Italy

Topics: Hepatitis B virus reactivation (HBVr), Capecitabine, breast cancer, Tenofovir, Immunosuppressive drug therapy (ISDT), Acute liver failure (ALF)
Year: 2016
OAI identifier: oai:arts.units.it:11368/2872769

Suggested articles


To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.